Hepatology International

, Volume 5, Issue 3, pp 767–773

Influence of serum HBV DNA load on recurrence of hepatocellular carcinoma after treatment with percutaneous radiofrequency ablation

Authors

    • Department of Gastroenterology, Graduate School of MedicineThe University of Tokyo
  • Haruhiko Yoshida
    • Department of Gastroenterology, Graduate School of MedicineThe University of Tokyo
  • Ryosuke Tateishi
    • Department of Gastroenterology, Graduate School of MedicineThe University of Tokyo
  • Kenichiro Enooku
    • Department of Gastroenterology, Graduate School of MedicineThe University of Tokyo
  • Eriko Goto
    • Department of Gastroenterology, Graduate School of MedicineThe University of Tokyo
  • Takahisa Sato
    • Department of Gastroenterology, Graduate School of MedicineThe University of Tokyo
  • Takamasa Ohki
    • Department of Gastroenterology, Graduate School of MedicineThe University of Tokyo
  • Ryota Masuzaki
    • Department of Gastroenterology, Graduate School of MedicineThe University of Tokyo
  • Jun Imamura
    • Department of Gastroenterology, Graduate School of MedicineThe University of Tokyo
  • Shuichiro Shiina
    • Department of Gastroenterology, Graduate School of MedicineThe University of Tokyo
  • Kazuhiko Koike
    • Department of Gastroenterology, Graduate School of MedicineThe University of Tokyo
  • Masao Omata
    • Department of Gastroenterology, Graduate School of MedicineThe University of Tokyo
Original Article

DOI: 10.1007/s12072-011-9255-1

Cite this article as:
Goto, T., Yoshida, H., Tateishi, R. et al. Hepatol Int (2011) 5: 767. doi:10.1007/s12072-011-9255-1

Abstract

Background

High serum load of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) is a strong risk factor of hepatocellular carcinoma (HCC) development, independent of hepatitis B e antigen, serum alanine aminotransferase level, and liver cirrhosis. We evaluated whether serum HBV DNA load is associated with the risk of recurrence of HBV-related HCC treated with radiofrequency ablation (RFA).

Methods

The study population was 69 consecutive patients with HBV-related HCC treated locally completely with RFA between January 2000 and September 2007. The risk factors for HCC recurrence were analyzed based on laboratory data, including serum HBV DNA load, together with tumor size and number using univariate and multivariate proportional hazard regression analyses.

Results

HCC recurrence was observed in 42 of 69 patients during the median observation period of 1.5 years. Cumulative recurrence rates at 1, 3, and 5 years were 26.5, 57.8, and 74.3%, respectively. In univariate analysis, albumin (<3.5 g/dl), platelet count (<150 × 103/mm3), prothrombin activity (PT) (<70%), Child-Pugh class B, serum HBV DNA load (>4.0 log10 copies/ml), and tumor number (>3) were associated with the recurrence at p ≤ 0.15. Multivariate Cox regression analysis with stepwise variable selection showed that the tumor number (risk ratio, 4.63; 95% CI, 1.50–14.25, P = 0.0076), low PT (3.39, 1.52–5.78, P = 0.0029), and high HBV DNA load (2.67, 1.16–6.14, P = 0.021) were independent risk factors for HCC recurrence.

Conclusion

Serum HBV DNA load is associated with the risk of recurrence of HBV-related HCC after RFA.

Keywords

Hepatitis B virusHepatocellular carcinomaRecurrenceRadiofrequency ablation

Abbreviations

HBV

Hepatitis B virus

HCC

Hepatocellular carcinoma

RFA

Radiofrequency ablation

HBsAg

Hepatitis B surface antigen

HCV-Ab

Hepatitis C virus antibody

CT

Computed tomography

HBeAg

Hepatitis B e antigen

HBeAb

Hepatitis B e antibody

AST

Aspartate aminotransferase

ALT

Alanine aminotransferase

PLT

Platelet count

PT

Prothrombin activity

AFP

Alpha-fetoprotein

AFP-L3

Lens culinaris agglutinin A-reactive fraction of AFP

DCP

Des-gamma-carboxy prothrombin

Copyright information

© Asian Pacific Association for the Study of the Liver 2011